Palatin Technologies Earnings Conference Call (Q1 2010)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 16 Calls Today's Calls

Call Details Palatin Technologies Earnings Conference Call (Q1 2010) Mon, Nov 16, 2009, 11:00 am Eastern Listen to the archived event audio About Palatin Technologies (AMEX:PTN) Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company’s products under development include PL-3994, a peptide mimetic natriuretic peptide receptor A agonist for the treatment of heart failure; Bremelanotide, a peptide melanocortin receptor agonist for the treatment of sexual dysfunction, targeting female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies; and PL-6983, a peptide melanocortin receptor agonist for the treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity, diabetes, and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies, Inc. has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Financials | Analyst Ratings